BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry: Predictors of Mortality and Survival Rates in SSc-Associated PAH. Arthritis Care & Research 2014;66:489-95. [DOI: 10.1002/acr.22121] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 11.9] [Reference Citation Analysis]
Number Citing Articles
1 Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Fritzler MJ, Pope J, Baron M, Hudson M; Canadian Scleroderma Research Group. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. Semin Arthritis Rheum 2020;50:1421-7. [PMID: 32245697 DOI: 10.1016/j.semarthrit.2020.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gelber AC. Lung transplantation for scleroderma: Strength in numbers. Joint Bone Spine 2018;85:5-7. [DOI: 10.1016/j.jbspin.2017.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
3 Highland KB. Recent advances in scleroderma-associated pulmonary hypertension. Curr Opin Rheumatol 2014;26:637-45. [PMID: 25203120 DOI: 10.1097/BOR.0000000000000114] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Deng J. Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Cardiothorac Surg 2021;16:311. [PMID: 34670595 DOI: 10.1186/s13019-021-01696-4] [Reference Citation Analysis]
5 Kolstad KD, Li S, Steen V, Chung L; PHAROS Investigators. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest 2018;154:862-71. [PMID: 29777655 DOI: 10.1016/j.chest.2018.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
6 Grzegorzewska AP, Seta F, Han R, Czajka CA, Makino K, Stawski L, Isenberg JS, Browning JL, Trojanowska M. Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep 2017;7:41605. [PMID: 28150703 DOI: 10.1038/srep41605] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
7 Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S; Australian Scleroderma Interest Group (ASIG). Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther 2017;19:42. [PMID: 28270192 DOI: 10.1186/s13075-017-1250-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
8 Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, McGoon M, Nicolls MR, Zamanian RT. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014;146:1494-504. [PMID: 24992469 DOI: 10.1378/chest.13-3014] [Cited by in Crossref: 85] [Cited by in F6Publishing: 70] [Article Influence: 12.1] [Reference Citation Analysis]
9 Saketkoo LA, Frech T, Varjú C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkmann ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirják L, Jensen K, Hinchclif M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, Steen V. A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Pract Res Clin Rheumatol 2021;35:101707. [PMID: 34538573 DOI: 10.1016/j.berh.2021.101707] [Reference Citation Analysis]
10 Thakkar V, Patterson KA, Stevens W, Wilson M, Roddy J, Sahhar J, Proudman S, Hissaria P, Nikpour M. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. Clin Rheumatol 2018;37:1563-71. [PMID: 29687288 DOI: 10.1007/s10067-018-4081-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Kanavos P, Taruscio D, Schieppati A, Iskrov G, Péntek M, Delgado C, von der Schulenburg JM, Persson U, Chevreul K, Fattore G; BURQOL-RD Research Network. Social/economic costs and health-related quality of life in patients with scleroderma in Europe. Eur J Health Econ 2016;17 Suppl 1:109-17. [PMID: 27038626 DOI: 10.1007/s10198-016-0789-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ho L, Hossen N, Nguyen T, Vo A, Ahsan F. Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension. Biomedicines 2022;10:170. [DOI: 10.3390/biomedicines10010170] [Reference Citation Analysis]
13 Hoeper MM, Simon R. Gibbs J. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014;23:450-7. [DOI: 10.1183/09059180.00007814] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
14 Barnes JK, Mouthon L, Mayes MD. Epidemiology, Environmental, and Infectious Risk Factors. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 11-24. [DOI: 10.1007/978-3-319-31407-5_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Legendre P, Mouthon L. Hypertension artérielle pulmonaire des connectivites. La Presse Médicale 2014;43:957-69. [DOI: 10.1016/j.lpm.2014.07.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
16 Patel JK, Rao Y, Strachan P. Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Trepostinil. Heart, Lung and Circulation 2018;27:183-9. [DOI: 10.1016/j.hlc.2017.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Methia N, Latreche S, Ait Mokhtar O, Monsuez JJ, Benkhedda S. Assessment for Pulmonary Artery Hypertension Using Clinical and Echocardiographic Criteria in Patients With Systemic Sclerosis. Am J Med Sci 2016;352:343-7. [PMID: 27776714 DOI: 10.1016/j.amjms.2016.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, Mclaughlin VV, Müller-ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis 2017;77:128-32. [DOI: 10.1136/annrheumdis-2017-211480] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rice LM, Mantero JC, Stratton EA, Warburton R, Roberts K, Hill N, Simms RW, Domsic R, Farber HW, Layfatis R. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2018;20:185. [PMID: 30115106 DOI: 10.1186/s13075-018-1679-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, Ahmad K, Bertoletti L, Camara B, Gomez E, Launay D, Montani D, Mornex JF, Prévot G, Sanchez O, Schott AM, Subtil F, Traclet J, Turquier S, Zeghmar S, Habib G, Reynaud-Gaubert M, Humbert M, Cottin V. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis Rheumatol 2021;73:295-304. [PMID: 32892515 DOI: 10.1002/art.41512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Doutre M. Quoi de neuf en médecine interne? Annales de Dermatologie et de Vénéréologie 2013;140:S263-72. [DOI: 10.1016/s0151-9638(13)70142-x] [Reference Citation Analysis]
22 Angeloudi E, Pagkopoulou E, Arvanitaki A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T. Cardiovascular Risk in Systemic Sclerosis. Curr Treat Options in Rheum 2020;6:282-98. [DOI: 10.1007/s40674-020-00152-z] [Reference Citation Analysis]
23 Yamamoto K, Takeda Y, Takeda Y, Naniwa T, Narita H, Ohte N. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents. BMC Res Notes 2014;7:359. [PMID: 24920465 DOI: 10.1186/1756-0500-7-359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Li X, Zhang C, Sun X, Yang X, Zhang M, Wang Q, Zhu Y. Prognostic factors of pulmonary hypertension associated with connective tissue disease: pulmonary artery size measured by chest CT. Rheumatology (Oxford) 2020;59:3221-8. [PMID: 32221604 DOI: 10.1093/rheumatology/keaa100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
25 Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Ther Adv Respir Dis 2017;11:327-40. [PMID: 28621173 DOI: 10.1177/1753465817713680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
26 Zhang Y, Zhang N, Sun X, Liu Q, Yuan X, Wang Q, Zhou L. Prognostic Significance of Small Pulmonary Vessel Alteration Measured by Chest Computed Tomography in Connective Tissue Diseases With Pulmonary Arterial Hypertension. Journal of Thoracic Imaging 2022;Publish Ahead of Print. [DOI: 10.1097/rti.0000000000000643] [Reference Citation Analysis]
27 Hester J, Ventetuolo C, Lahm T. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. Compr Physiol 2019;10:125-70. [PMID: 31853950 DOI: 10.1002/cphy.c190011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
28 Foderaro A, Ventetuolo CE. Pulmonary Arterial Hypertension and the Sex Hormone Paradox. Curr Hypertens Rep 2016;18:84. [PMID: 27832457 DOI: 10.1007/s11906-016-0689-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
29 Lechartier B, Humbert M. Pulmonary arterial hypertension in systemic sclerosis. Presse Med 2021;50:104062. [PMID: 33548377 DOI: 10.1016/j.lpm.2021.104062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Singh JA, Cleveland JD. Serious infections in people with systemic sclerosis: a national US study. Arthritis Res Ther 2020;22:163. [PMID: 32600412 DOI: 10.1186/s13075-020-02216-w] [Reference Citation Analysis]
31 Hung G, Mercurio V, Hsu S, Mathai SC, Shah AA, Mukherjee M. Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis. Curr Rheumatol Rep 2019;21. [DOI: 10.1007/s11926-019-0867-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
32 Giucă A, Mihai C, Jurcuț C, Gheorghiu AM, Groșeanu L, Dima A, Săftoiu A, Coman IM, Popescu BA, Jurcuț R. Screening for Pulmonary Hypertension in Systemic Sclerosis-A Primer for Cardio-Rheumatology Clinics. Diagnostics (Basel) 2021;11:1013. [PMID: 34206055 DOI: 10.3390/diagnostics11061013] [Reference Citation Analysis]
33 Ibrahim YF, Shults NV, Rybka V, Suzuki YJ. Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis. J Pharmacol Exp Ther 2017;363:20-34. [PMID: 28760737 DOI: 10.1124/jpet.117.239921] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
34 Saygin D, Domsic RT. Pulmonary Arterial Hypertension In Systemic Sclerosis: Challenges In Diagnosis, Screening And Treatment. Open Access Rheumatol 2019;11:323-33. [PMID: 31920409 DOI: 10.2147/OARRR.S228234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
35 Singh JA, Cleveland JD. How Systemic Sclerosis Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty. J Rheumatol 2020;47:1218-23. [PMID: 31615909 DOI: 10.3899/jrheum.190783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Al Otair HA, Idrees MM, Saleemi SA, Eltoukhy AM, Alhijji AA, Al Habeeb WA, Omair MA. Pulmonary arterial hypertension in Saudi patients with systemic sclerosis: Clinical and hemodynamic characteristics and mortality. Ann Thorac Med 2019;14:83-9. [PMID: 30745940 DOI: 10.4103/atm.ATM_33_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, Xu D, Tian Z, Wei W, Zuo X, Zhang M, Zhu P, Ye S, Zhang W, Zheng Y, Qi W, Li Y, Zhang Z, Ding F, Gu J, Liu Y, Wang Y, Zhao Y, Zeng X. Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China. Eur Respir J 2020;56:1902157. [PMID: 32616590 DOI: 10.1183/13993003.02157-2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Simpson CE, Damico RL, Hummers L, Khair RM, Kolb TM, Hassoun PM, Mathai SC. Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm Circ 2019;9:2045894019859477. [PMID: 31384431 DOI: 10.1177/2045894019859477] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Kato M, Atsumi T. Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects. Eur J Clin Invest 2018;48. [PMID: 29285766 DOI: 10.1111/eci.12876] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
40 Argula RG, Karwa A, Lauer A, Gregg D, Silver RM, Feghali-Bostwick C, Schanpp LM, Egbert K, Usher BW, Ramakrishnan V, Hassoun PM, Strange C. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc 2017;14:682-9. [PMID: 28282243 DOI: 10.1513/AnnalsATS.201608-655OC] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Poudel DR, Jayakumar D, Danve A, Sehra ST, Derk CT. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int 2018;38:1847-58. [PMID: 29116439 DOI: 10.1007/s00296-017-3826-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
42 Simpson CE, Kolb TM, Hsu S, Zimmerman SL, Corona‐villalobos CP, Mathai SC, Damico RL, Hassoun PM. Ventricular mass discriminates pulmonary arterial hypertension as redefined at the Sixth World Symposium on Pulmonary Hypertension. Pulm circ 2022;12. [DOI: 10.1002/pul2.12005] [Reference Citation Analysis]
43 Coirier V, Chabanne C, Jouneau S, Belhomme N, Ballerie A, Cazalets C, Sobanski V, Hachulla É, Jégo P, Lescoat A. Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. Diagnostics (Basel) 2021;11:1738. [PMID: 34679436 DOI: 10.3390/diagnostics11101738] [Reference Citation Analysis]
44 De Almeida Chaves S, Porel T, Mounié M, Alric L, Astudillo L, Huart A, Lairez O, Michaud M, Prévot G, Ribes D, Sailler L, Gaches F, Adoue D, Pugnet G. Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality. Arthritis Res Ther 2021;23:295. [PMID: 34876194 DOI: 10.1186/s13075-021-02672-y] [Reference Citation Analysis]
45 Mathai SC, Hummers LK. Pulmonary Hypertension Associated with Connective Tissue Disease. In: Dellaripa PF, Fischer A, Flaherty KR, editors. Pulmonary Manifestations of Rheumatic Disease. New York: Springer; 2014. pp. 139-66. [DOI: 10.1007/978-1-4939-0770-0_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Gupta S, Gupta A, Rehman S, Ocak I, Domsic RT, Schneider F, George MP. Pulmonary veno-occlusive disease is highly prevalent in scleroderma patients undergoing lung transplantation. ERJ Open Res 2019;5:00168-2018. [PMID: 30775371 DOI: 10.1183/23120541.00168-2018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
47 Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, Attucks OC, Franklin S, Levonen AL, Kensler TW, Dinkova-Kostova AT. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019;18:295-317. [PMID: 30610225 DOI: 10.1038/s41573-018-0008-x] [Cited by in Crossref: 346] [Cited by in F6Publishing: 332] [Article Influence: 115.3] [Reference Citation Analysis]
48 Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015;17:7. [PMID: 25596924 DOI: 10.1186/s13075-015-0517-5] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
49 Bauer Y, de Bernard S, Hickey P, Ballard K, Cruz J, Cornelisse P, Chadha-Boreham H, Distler O, Rosenberg D, Doelberg M, Roux S, Nayler O, Lawrie A. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. Eur Respir J 2021;57:2002591. [PMID: 33334933 DOI: 10.1183/13993003.02591-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Yang EI. Perioperative management of patients with pulmonary hypertension for non-cardiac surgery. Curr Rheumatol Rep 2015;17:15. [PMID: 25740702 DOI: 10.1007/s11926-014-0490-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
51 Vilela VS, Dias MM, Salgado ÂA, da Silva BRA, Lopes AJ, Bessa EJC, Bruno LP, da Costa CH, Levy RA, Rufino R. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. BMC Pulm Med 2021;21:251. [PMID: 34325685 DOI: 10.1186/s12890-021-01618-z] [Reference Citation Analysis]
52 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M; Australian Scleroderma Interest Group (ASIG). Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med 2016;16:134. [PMID: 27677579 DOI: 10.1186/s12890-016-0296-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
53 Valenzuela A, Nandagopal S, Steen VD, Chung L. Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Rheum Dis Clin North Am 2015;41:489-506. [PMID: 26210131 DOI: 10.1016/j.rdc.2015.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
54 Odler B, Foris V, Gungl A, Müller V, Hassoun PM, Kwapiszewska G, Olschewski H, Kovacs G. Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Front Physiol 2018;9:587. [PMID: 29971007 DOI: 10.3389/fphys.2018.00587] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
55 Syed Gaggatur N, Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Sange I. Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. Cureus 2021;13:e17291. [PMID: 34552830 DOI: 10.7759/cureus.17291] [Reference Citation Analysis]
56 Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. Eur Heart J Suppl 2019;21:K9-K20. [PMID: 31857796 DOI: 10.1093/eurheartj/suz204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
57 Lee MH, Bull TM. The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis. F1000Res 2019;8:F1000 Faculty Rev-2124. [PMID: 32025283 DOI: 10.12688/f1000research.20313.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Del Papa N, Pignataro F, Zaccara E, Maglione W, Minniti A. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis. Front Immunol 2018;9:2390. [PMID: 30386340 DOI: 10.3389/fimmu.2018.02390] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
59 Sung YK, Chung L. Connective tissue disease-associated pulmonary arterial hypertension. Rheum Dis Clin North Am 2015;41:295-313. [PMID: 25836644 DOI: 10.1016/j.rdc.2015.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
60 Colalillo A, Grimaldi MC, Vaiarello V, Pellicano C, Leodori G, Gigante A, Romaniello A, Rosato E. In systemic sclerosis TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis. Rheumatology (Oxford) 2021:keab748. [PMID: 34605890 DOI: 10.1093/rheumatology/keab748] [Reference Citation Analysis]
61 Haley S, Shah D, Romero F, Summer R. Scleroderma-related lung disease: are adipokines involved pathogenically? Curr Rheumatol Rep 2013;15:381. [PMID: 24173692 DOI: 10.1007/s11926-013-0381-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Badlam JB, Austin ED. Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension. Eur Respir J 2018;51:1801058. [PMID: 29954927 DOI: 10.1183/13993003.01058-2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Gleason JB, Patel KB, Hernandez F, Hadeh A, Highland KB, Rahaghi F, Mehta JP. Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease. Lung 2017;195:403-9. [PMID: 28456874 DOI: 10.1007/s00408-017-0005-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Condliffe R, Howard LS. Connective tissue disease-associated pulmonary arterial hypertension. F1000Prime Rep 2015;7:06. [PMID: 25705389 DOI: 10.12703/P7-06] [Cited by in Crossref: 33] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
65 Thakkar V, Lau EM. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol 2016;30:22-38. [PMID: 27421214 DOI: 10.1016/j.berh.2016.03.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
66 Farge D, Burt RK, Oliveira MC, Mousseaux E, Rovira M, Marjanovic Z, de Vries-Bouwstra J, Del Papa N, Saccardi R, Shah SJ, Lee DC, Denton C, Alexander T, Kiely DG, Snowden JA. Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners. Bone Marrow Transplant 2017;52:1495-503. [PMID: 28530671 DOI: 10.1038/bmt.2017.56] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
67 Sundaram SM, Chung L. An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature. Curr Rheumatol Rep 2018;20:10. [PMID: 29488016 DOI: 10.1007/s11926-018-0709-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
68 Pestaña-fernández M, Rubio-rivas M, Tolosa-vilella C, Guillén-del-castillo A, Freire M, Vargas-hitos JA, Todolí-parra JA, Rodríguez-carballeira M, Marín-ballvé A, Espinosa G, Colunga-argüelles D, Ortego-centeno N, Trapiella-martínez L, Carbonell-muñoz C, Pla-salas X, Perales-fraile I, Corbella X, Fonollosa-pla V, Simeón-aznar CP. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study. J Rheumatol 2020;47:89-98. [DOI: 10.3899/jrheum.180595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Aithala R, Alex AG, Danda D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis 2017;20:5-24. [PMID: 28205373 DOI: 10.1111/1756-185X.13001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
70 Kongkaew S, Rungrotmongkol T, Punwong C, Noguchi H, Takeuchi F, Kungwan N, Wolschann P, Hannongbua S. Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis. Sci Rep 2019;9:745. [PMID: 30679605 DOI: 10.1038/s41598-018-37038-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Argula RG, Ward C, Feghali-Bostwick C. Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH). Ther Clin Risk Manag 2019;15:1427-42. [PMID: 31853179 DOI: 10.2147/TCRM.S219024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 van Laar JM, Naraghi K, Tyndall A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford) 2015;54:2126-33. [PMID: 25953700 DOI: 10.1093/rheumatology/kev117] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
73 Singh JA, Cleveland JD. Systemic sclerosis is associated with knee arthroplasty outcomes: a National US study. Clin Rheumatol 2020;39:85-92. [PMID: 31444650 DOI: 10.1007/s10067-019-04754-4] [Reference Citation Analysis]
74 Abe N, Kato M, Kono M, Fujieda Y, Ohira H, Tsujino I, Oyama-Manabe N, Oku K, Bohgaki T, Yasuda S, Atsumi T. Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. Rheumatology (Oxford) 2020;59:622-33. [PMID: 31424519 DOI: 10.1093/rheumatology/kez336] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, Celermajer D, Zochling J, Proudman S, Nikpour M; Australian Scleroderma Interest Group (ASIG). Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther 2017;19:122. [PMID: 28576149 DOI: 10.1186/s13075-017-1341-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
76 Bukiri H, Volkmann ER. Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 2022;64:102211. [PMID: 35447517 DOI: 10.1016/j.coph.2022.102211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Kato M, Sugimoto A, Atsumi T. Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. Expert Rev Clin Immunol 2020;16:993-1004. [PMID: 32975145 DOI: 10.1080/1744666X.2021.1825940] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Adegunsoye A, Oldham JM, Valenzi E, Lee C, Witt LJ, Chen L, Montner S, Chung JH, Noth I, Vij R, Strek ME, Husain AN. Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Arch Pathol Lab Med 2017;141:960-9. [PMID: 28467213 DOI: 10.5858/arpa.2016-0427-OA] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
79 Moll M, Christmann RB, Zhang Y, Whitfield ML, Wang YM, Rice L, Stratton E, Lafyatis R, Farber HW. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. J Scleroderma Relat Disord 2018;3:242-8. [PMID: 30498788 DOI: 10.1177/2397198318764780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
80 Showalter K, Ma X, Pinheiro L, Sobol I, Gordon JK, Mehta B. Thirty-day hospital readmission in systemic sclerosis associated pulmonary hypertension: A nationwide study. Semin Arthritis Rheum 2021;51:324-30. [PMID: 33465591 DOI: 10.1016/j.semarthrit.2021.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Dobrota R, Mihai C, Distler O. Personalized Medicine in Systemic Sclerosis: Facts and Promises. Curr Rheumatol Rep 2014;16. [DOI: 10.1007/s11926-014-0425-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
82 Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, Steen V, Chung L; PHAROS Investigators. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. Semin Arthritis Rheum 2015;45:309-14. [PMID: 26210782 DOI: 10.1016/j.semarthrit.2015.06.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
83 Almaaitah S, Highland KB, Tonelli AR. Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Integr Blood Press Control 2020;13:15-29. [PMID: 32280271 DOI: 10.2147/IBPC.S232038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
84 Pope JE. Pulmonary arterial hypertension in scleroderma: care gaps in screening. Arthritis Res Ther 2017;19:128. [PMID: 28587630 DOI: 10.1186/s13075-017-1347-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
85 Sanges S, Launay D, Rhee RL, Sitbon O, Hachulla É, Mouthon L, Guillevin L, Rottat L, Montani D, De Groote P, Cottin V, Magro P, Prévot G, Bauer F, Bergot E, Chabanne C, Reynaud-Gaubert M, Leroy S, Canuet M, Sanchez O, Gut-Gobert C, Dauphin C, Pison C, Boissin C, Habib G, Clerson P, Conesa F, Cordier JF, Kawut SM, Simonneau G, Humbert M. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2016;75:1457-65. [PMID: 26324844 DOI: 10.1136/annrheumdis-2015-207336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
86 Lammi MR, Mathai SC, Saketkoo LA, Domsic RT, Bojanowski C, Furst DE, Steen VD; Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Arthritis Rheumatol 2016;68:740-8. [PMID: 26479414 DOI: 10.1002/art.39478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
87 Pugnet G, Marjanovic Z, Deligny C, Boussardon K, Benzidia I, Puyade M, Lansiaux P, Vandecasteele E, Smith V, Farge D. Reproducibility and Utility of the 6-minute Walk Test in Systemic Sclerosis. J Rheumatol 2018;45:1273-80. [PMID: 29961695 DOI: 10.3899/jrheum.170994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
88 Simms RW. Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma. Arthritis Rheumatol 2020;72:1415-26. [PMID: 32562363 DOI: 10.1002/art.41406] [Reference Citation Analysis]
89 Thakkar V, Nikpour M, Stevens WM, Proudman SM. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension: Pulmonary hypertension in scleroderma. Intern Med J 2015;45:248-54. [DOI: 10.1111/imj.12691] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Chung L, Kawut SM. Connective tissue disease-associated pulmonary arterial hypertension: "Beijing style". Eur Respir J 2014;44:839-41. [PMID: 25271223 DOI: 10.1183/09031936.00090814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
91 Gashouta MA, Humbert M, Hassoun PM. Update in systemic sclerosis-associated pulmonary arterial hypertension. La Presse Médicale 2014;43:e293-304. [DOI: 10.1016/j.lpm.2014.06.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
92 García Hernández FJ, Castillo Palma MJ, Montero Mateos E, González León R, López Haldón JE, Sánchez Román J. [Screening of pulmonary hypertension in a Spanish cohort of patients with systemic sclerosis]. Med Clin (Barc) 2016;146:1-7. [PMID: 26169331 DOI: 10.1016/j.medcli.2015.04.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Petrauskas LA, Saketkoo LA, Kazecki T, Saito S, Jaligam V, deBoisblanc BP, Lammi MR. Use of red cell distribution width in a population at high risk for pulmonary hypertension. Respir Med 2019;150:131-5. [PMID: 30961939 DOI: 10.1016/j.rmed.2019.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Di Benedetto P, Guggino G, Manzi G, Ruscitti P, Berardicurti O, Panzera N, Grazia N, Badagliacca R, Riccieri V, Vizza CD, Radchenko G, Liakouli V, Ciccia F, Cipriani P, Giacomelli R. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Res Ther 2020;22:127. [PMID: 32487240 DOI: 10.1186/s13075-020-02218-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Joven BE, Escribano P, Andreu JL, Loza E, Jimenez C, de Yebenes MJG, Ruiz-cano MJ, Carmona L, Carreira PE. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism 2018;47:870-6. [DOI: 10.1016/j.semarthrit.2017.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
96 Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, Nagaraja V, McLaughlin V, Khanna D. Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. Arthritis Rheumatol 2021;73:1731-7. [PMID: 33760392 DOI: 10.1002/art.41732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
97 Karampitsakos T, Tzouvelekis A, Chrysikos S, Bouros D, Tsangaris I, Fares WH. Pulmonary hypertension in patients with interstitial lung disease. Pulm Pharmacol Ther 2018;50:38-46. [PMID: 29605286 DOI: 10.1016/j.pupt.2018.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]